← Back
Immunic
IMUX · listed on Nasdaq · worth $107.79 million
$7.94
+4.47% today
No insider bought or sold Immunic stock on the market in the last year.
◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
Reverse split 1-for-10 in Apr 2026. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what IMUX ever actually traded at. The drop is real, but those huge old numbers aren't.
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
12.0M shares
88% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
No insider bought or sold Immunic stock on the market in the last year. The reports below are share awards and other paperwork.
Big investors
People and funds that reported owning 5% or more of Immunic, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company. · updateAberdeen Group8.0%Nov 2
Filed by someone who owns 5% or more and does not plan to influence the company.Orbimed Advisors LLC5.3%Aug 14
Filed by someone who owns 5% or more and does not plan to influence the company. · updateSoleus Capital Master Fund4.9%Aug 13
Filed by someone who owns 5% or more and does not plan to influence the company. · updateIntegrated Core Strategies (US) LLC6.9%Aug 6
Filed by someone who owns 5% or more and does not plan to influence the company.Laurion Capital Management LP6.1%Aug 4
All reports
Every insider trade and SEC report we hold for Immunic.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Jun 16, 2025BoughtDuane NashJun 16, 2025 · Traded Jun 13, 2025 · Executive Chairman+56%20,000 @ $0.8347$16.7K
Jun 9, 2025BoughtJason TardioJun 9, 2025 · Traded Jun 5, 2025 · President and COO+100%12,512 @ $0.7900$9.9K
Jun 6, 2025BoughtDaniel VittJun 6, 2025 · Traded Jun 4, 2025 · CEO and Director+52%15,000 @ $0.7700$11.6K
Jun 5, 2025BoughtJoerg NeermannJun 5, 2025 · Traded Jun 4, 2025 · Director+41%70,000 @ $0.7700$53.9K
2 more with Pro →Analysts, earnings and news
Analysts' price target
$43.09 average
11 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 4 quarters above
Q2 '26−$0.80 a share+$0.36
Q1 '26−$1.08 a share−$0.12
Q4 '25−$0.70 a share+$0.41
Q3 '25−$1.30 a share+$0.47